Month: January 2024

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Shareholders: As we begin a new year, I wanted to take a moment to thank you for your support of Alterity, reflect on our accomplishments in 2023, and lay out our key milestones for 2024. We remain steadfastly committed to developing new treatments for individuals living with neurodegenerative diseases. 2023 was a critical year for us and I am pleased to report that we hit all of our intended milestones. We have an extremely...

French limited company (Société anonyme) with registered capital of 106,945,095 euros Registered office: 14, rue Royale, 75008 Paris 632 012 100 R.C.S. Paris Legal Entity Identifier: 529900JI1GG6F7RKVI53Pursuant to article L-233-8 II of the French “Code de Commerce” and 223-16 of the AMF’s General Regulations:Total number of shares 534,725,475Number of real voting rights (excluding treasury shares) 534,725,475Theoretical number of voting rights (including treasury shares*)(*) pursuant to article 223-11 of the AMF’s General Regulations 534,725,475About L’Oréal For over 110 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as...

CHATTANOOGA, Tenn., Jan. 22, 2024 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announced the company’s board of directors (the “Board”) appointed Mr. Patrick S. Shannon and Mr. Jeffrey (“Jeff”) T. Jackson, new independent directors, to the Board effective as of January 18, 2024. Mr. William Bradley (“Brad”) Southern, an independent director, informed the Board he will be retiring as a member of the Board effective January 18, 2024. With the election of Mr. Shannon and Mr. Jackson, and the retirement of Mr. Southern, the size of the Board increased to 11 directors, 10 of whom are independent directors. Mr. Shannon will also serve as a member of the Audit Committee of the Board and Mr. Jackson will serve as a member of the Compensation Committee of the Board. William Gehl, Chairman of Astec’s Board of Directors, said,...

Leading Power Generation Solutions Provider to Exhibit at PowerGen in New Orleans WOOD DALE, Ill., Jan. 22, 2024 (GLOBE NEWSWIRE) — Power Solutions International, Inc. (the “Company” or “PSI”) (OTC Pink: PSIX), a leader in the design, engineering and manufacture of emission-certified engines and power systems, is excited to announce its participation in PowerGen International, taking place from January 23 to January 25 at the Ernest N. Morial Convention Center in New Orleans. The event brings together industry professionals, experts and innovators to explore the latest advancements in power generation technologies. PSI is proud to be a part of the event, showcasing its 20-liter and 2.4-liter Turbo engines in Booth 2544. The engines are part of PSI’s Power Systems line, known in the industry for their exceptional performance, reliability...

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. “I am excited to welcome Kaya to Neumora. As we progress toward the potential commercialization of navacaprant and further advance our pipeline, her extensive commercial expertise in neuropsychiatry will...

COLMAR, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) — Dorman Products, Inc. (NASDAQ:DORM) hasn’t lost any momentum from a successful 2023 that featured more than 3,000 new product launches, and is announcing 325 new motor vehicle parts to start the new year. These January 2024 releases represent millions of new sales opportunities for automotive parts distributors, retailers, and repair shops and reinforce Dorman’s position as a leading aftermarket provider of comprehensive powertrain repair solutions. This month’s new releases include an innovative Dorman® OE FIX™ transmission oil cooler bypass valve, with coverage for approximately 1.5 million select Chevrolet, GMC and Cadillac SUVs and pickup trucks. On certain models, when the transmission overheats, doesn’t generate sufficient heat, or leaks fluid, it can be due to corrosion,...

Mercury’s DRF2580 System-On-ModuleMercury’s DRF2580 System-On-ModuleANDOVER, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing power to the edge, today introduced a Direct RF system-on-module (SOM) that uses Intel Agilex FPGAs to detect and process adversary emissions from a wide portion of the electromagnetic spectrum. Direct RF components and modules directly digitize radio frequency signals at the antenna signal frequency, eliminating the analog signal down conversion stages required by legacy hardware. This approach requires extremely fast converters, high bandwidth digital data links, and powerful real-time digital signal processing. The results are reductions size, weight, power, cost, and latency...

Figure 1Caña Brava Project: drone-borne RTP magnetic anomaly map showing the alteration footprints over Caña Brava 1 and Luz Maria.Figure 2Luz Maria Prospect: map showing the outcroppingintrusions, with the average Cu and Mo grades, coincident magnetic anomalies, and other possible intrusion centres below the sedimentary and colluvium cover.TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Western Metallica Resources Corp. (TSXV: WMS) (“Western Metallica” or the “Company”) is pleased to report on a recent discovery at Luz Maria, one of two prospects within the Company’s Caña Brava Project, where recent geochemical and drone-borne magnetometry surveys have confirmed a ~2.7 km by ~1.5 km potassic and phyllic alteration, typical of Andean Cu-Mo porphyry systems, associated to magnetic anomalies and consistent copper grades...

– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program. “We are sharpening our clinical focus on the rapidly...